glp-1-ras Frontiers GLP-1 RAs: Beyond Glycemic Control

*In a study of 3,250 WW Clinic patients, patients that were prescribed a GLP-1 lost on average 21% of their body weight at 12 months

Delivery of pineal melatonin to the brain and SCN: role of canaliculi, cerebrospinal fluid, tanycytes and VirchowRobin perivascular spaces

However, nitrate/nitrite demonstrated a moderate effect size ( r = 0.35) for increase from pre (139.50 18.35 molL -1 6 hr -1 ) to post (172.40 21.75 molL -1 6 hr -1 ) intervention with ALCA, and the magnitude of decrease following feeding was not as pronounced as with placebo

The LR3 modification makes this more potent

This will improve both, the periprocedural safety and efficacy of EGDs, in patients taking GLP-1 RAs

You enter a 2-month rest period